almonertinib + gefitinib

Almonertinib + gefitinib is a combination of two epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors used in the treatment of EGFR-mutated non-small-cell lung cancer (NSCLC). Almonertinib is a third-generation EGFR-TKI that selectively inhibits mutant forms of EGFR including T790M mutation with less activity against wild-type EGFR, reducing adverse effects such as rash and diarrhea. Gefitinib is a first-generation EGFR-TKI that reversibly inhibits the ATP-binding site of the EGFR tyrosine kinase, blocking downstream signaling pathways involved in tumor cell proliferation. The combination aims to overcome resistance mechanisms and improve efficacy in NSCLC patients harboring specific EGFR mutations. Clinical trials have shown almonertinib has superior progression-free survival compared to gefitinib alone. The drugs are orally administered small molecules developed primarily for targeted therapy in lung cancer.

Other names

HS-10296 (almonertinib)